LIGAND PHARMACEUTICALS INCORPORATED Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations of $831.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2026-03-31 was -$59.83M.
- LIGAND PHARMACEUTICALS INCORPORATED cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2025-03-31 was -$24.24M, a 189.32% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2024-03-31 was $27.14M.
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 3 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 3 month as first filed | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 6 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 6 month as first filed | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 9 month |
|---|---|---|---|---|---|
| 2026-06-30 | $831.77M 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | -$59.83M 10-Q · filed 2026-05-08 | ||||
| 2025-09-30 | $67.07M 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | -$1.82M 10-Q · filed 2026-08-07 | -$4.64M 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | -$24.24M 10-Q · filed 2026-05-08 | -$24.32M 10-Q · filed 2025-05-09 | |||
| 2024-09-30 | $40.66M 10-Q · filed 2025-11-07 | ||||
| 2024-06-30 | -$4.82M 10-Q · filed 2025-08-08 | ||||
| 2024-03-31 | $27.14M 10-Q · filed 2025-05-09 |